Biomarin Pharmaceutical (US:BMRN) — Company Overview, News & Financial Data
BioMarin Pharmaceutical develops therapies for rare genetic diseases, aiming to improve health outcomes for patients.
About Biomarin Pharmaceutical
BioMarin Pharmaceutical (NASDAQ:BMRN) is a biotechnology company dedicated to the development and commercialization of innovative therapies for serious and life-threatening rare genetic diseases. Their operations range from advanced pre-clinical work to the commercial sale of pharmaceuticals. Their projects and objectives focus on providing new treatments for rare metabolic diseases, with a pipeline that includes advanced therapies for phenylketonuria, achondroplasia, and hemophilia, among others. Their mission is to improve the health outcomes and quality of life for these patients, who often have few, if any, medical options, often transforming their lives.
Snapshot
Operations
Products and/or services of Biomarin Pharmaceutical
- ROCTAVIAN™ (valoctocogene roxaparvovec-rvox): This is a gene therapy treatment for severe hemophilia A.
- VOXZOGO® (vosoritide): This is a growth hormone receptor agonist indicated for the treatment of patients with achondroplasia who have stopped growing.
- BRINEURA® (cerliponase alfa): This is an enzyme replacement therapy for the treatment of patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
- KUVAN® (sapropterin dihydrochloride): This is a cofactor replacement therapy for the treatment of patients with phenylketonuria (PKU) who have a specific genetic variant (PAH deficiency).
- NAGLAZYME® (galsulfase): This is an enzyme replacement therapy for the treatment of patients with mucopolysaccharidosis type VI (MPS VI).
- ALDURAZYME® (laronidase): This is an enzyme replacement therapy for the treatment of patients with mucopolysaccharidosis type I (MPS I).
Biomarin Pharmaceutical executive team
- Mr. Alexander HardyPresident, CEO & Director
- Mr. Brian R. Mueller CPACFO & Executive VP
- Mr. George Eric Davis J.D.Executive VP, Chief Legal Officer & Secretary
- Ms. Cristin HubbardExecutive VP & Chief Commercial Officer
- Dr. Gregory Friberg M.D.Executive VP and Chief Research & Development Officer
- Ms. Rashmi RamchandaniVP, Chief Accounting Officer & Principal Accounting Officer
- Dr. C. Greg Guyer Ph.D.Executive VP & CTO
- Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early Development
- Mr. Arpit DaveExecutive Vice President, Chief Digital & Information Officer
- Ms. Amy WiremanExecutive VP & Chief People Officer